How Astellas’ CFO weighs cash management, leadership and ‘nomikai’ culture

How Astellas’ CFO weighs cash management, leadership and ‘nomikai’ culture

This audio is auto-generated. Please let us know if you have feedback.

Astellas is one of Japan’s largest drugmakers, generating more than ¥1 trillion in revenue in the first half of FY2025, or roughly $6.4 billion. Its global footprint spans the United States, Europe and Asia, placing ongoing pressure on finance to support growth, manage volatility and guide long-term strategy.

Its CFO Atsushi Kitamura brings a unique cross-industry background to the organization, with experience in consumer goods, logistics, restaurants and technology. Since joining Astellas in late 2023, he has focused on strengthening the balance sheet, improving cash productivity and deepening collaboration across the business as the company prepares for an important period of transition.

Kitamura also sees cultural shifts shaping how teams work. He spoke about the decline of nomikai, Japan’s long-standing tradition of after-work drinking and socializing with colleagues, and how younger employees are redefining communication and connection. In a recent interview with CFO.com, he shares his views on technology ROI, leadership during uncertainty and the evolving expectations facing today’s finance teams.


Atsushi Kitamura

Atsushi Kitamura

Permission granted by Atsushi Kitamura

 

CFO, Astellas

First CFO position: 2016

Notable previous employers:

  • Pioneer Corporation
  • Skylark
  • TNT Express
  • Procter & Gamble

This interview has been edited for brevity and clarity.

ADAM ZAKI: Your company has gone through acquisitions and other changes. How do you keep your team motivated during uncertainty, whether it is a deal, economic pressure or market disruption?

ATSUSHI KITAMURA: I am still learning. But a few things stand out.

In uncertainty, we need to focus on what we can control. I cannot control exchange rates or geopolitical risks. But if the environment is volatile, we can increase flexibility. We can build more buffers into operations. We can optimize costs. If the downside never comes, then we will enjoy better results. But if something does happen, we are prepared. So, I may put more stretch into targets and ask the team to generate more ideas to create that buffer. That is something we can control.

Second, clarity and communication are critical. People struggle when communication is unclear or when visibility is low.

In pharma, cash flow is relatively strong, but risk is also very high because science is science. Success rates [in R&D] are low. When you have a good asset, cash flow for several years is predictable, but then the loss of exclusivity comes. That is the cycle.

In our case, we are facing a major loss of exclusivity on a large asset, so we need to transform. My job as CFO is to provide great visibility across several scenarios. If one scenario happens, here is what we will see. If another happens, here is what the impact will be. And in each scenario, here are the backups. It’s not the end of the game in any scenario.

By showing scenarios, showing preparation and giving transparency, we create psychological safety. People can see that we are not just reacting — we are preparing and making progress. That helps motivation during uncertainty.

Pharma is notoriously capital-intensive, focused heavily on R&D and requires great capital allocation on your part. Are there any unique considerations in your planning for next year, and how are you preparing finance to support major decisions in 2026?

The priority is to invest in future growth like technology, R&D and also business development and licensing when needed. The second priority is a sustainable return to shareholders through stable dividend growth. And third, whenever we have surplus cash, we return it immediately through share buybacks. These priorities remain the same.


“The difficult work starts now. This year and next year are about preparing for real execution of [our] transformation.”

Atsushi Kitamura

CFO, Astellas


However, two and a half years ago, just before I joined, Astellas made a major acquisition which was a $6 billion transaction. Before that acquisition, we were in a net cash position. After the acquisition, we shifted to a net debt position. So strengthening the balance sheet became a major priority.

One reason I was asked to join was to improve the balance sheet. So while the capital allocation framework is unchanged, we must accelerate debt reduction. That requires a strong focus on cash productivity.

I come from industries where cash discipline is essential. I’ve worked in businesses with difficult economics, high volatility and limited margin for error. During COVID, cash management was a daily struggle. That experience shaped how I approach finance today.

At Astellas, we are focusing on cash productivity, working capital improvement and optimizing cash on hand. Historically, we had large cash balances, but now with debt, we need to rebalance, reduce excess cash, free up working capital and pay down debt. That also means increasing profitability to reduce leverage.

link